OUR PIPELINE
Indication
IND-enabling
*Phase I/II
BLA
Partner
Lenzilumab
Break CAR-T Efficacy/Toxicity Linkage
Lenz prophylaxis as sequenced therapy with Yescarta in r/r DLBCL
ZUMA-19
Prevention/Treatment of Acute GvHD
Allogeneic Hematopoietic Stem Cell Transplant
CAR-Ts
FasterCARs
Novel multiple combination CARs w/ GM-CSF k/o: increase efficacy and safety for hematologic & solid cancers
EphA3 – CAR
with GM-CSF k/o for hematologic & solid cancers
EMR1 – CAR
with GM-CSF k/o for eosinophilic disorders
*Potential for Breakthrough designation and accelerated path to approval following successful completion of phase I/II studies, similar to Yescarta and Kymriah